Loading
A phase 1/2 trial of ADI-270, Fludarabine, Cyclophosphamide in renal cell carcinoma, run by Adicet Therapeutics, active and no longer recruiting.
A Phase 1/2 Trial of ADI-270 in ccRCC is a phase 1/2 interventional study registered as NCT06480565 by Adicet Therapeutics, with 60 participants planned, started 2024-12-12 and due to reach its primary completion in 2026-12. Interventions recorded: ADI-270, Fludarabine, Cyclophosphamide. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Clear cell renal cell carcinoma, Fludarabine, Renal cell carcinoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.